Langley 2011.

Methods	This was a randomised, placebo‐controlled trial. This abstract used data from the 28‐week phase IV trial, REACH (randomized, placebo‐controlled evaluation of adalimumab for treatment of adults with moderate to severe chronic plaque psoriasis involving hands, feet, or both; NCT00735787).
Participants	Inclusion criteria of the trial Participants with moderate to severe chronic plaque psoriasis involving hands, feet, or both
Interventions	Adalimumab Placebo Participants were randomised 2:1 to adalimumab (80 mg at week 0, 40 mg every other week from weeks 1 to 27) or placebo (placebo at weeks 1 to 15, 80 mg adalimumab at week 16, 40 mg every other week from weeks 17 to 27).
Outcomes	Outcomes of the trial Nail Psoriasis Severity Index (NAPSI)
Notes	This was an abstract conference publication.